Coadministration of DPP-4 inhibitor and insulin therapy does not further reduce the risk of cardiovascular events compared with DPP-4 inhibitor therapy in diabetic foot patients: a nationwide population-based study

BACKGROUND: The effect of combined insulin and dipeptidyl peptidase-4 inhibitor (DPP4i) therapy on major adverse cardiovascular events (MACEs) in patients with diabetic foot is unclear. METHODS: We conducted this nationwide cohort study using longitudinal claims data obtained from the Taiwan Nationa...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Diabetol Metab Syndr
Main Authors: Lin, Yi-Hsuan, Huang, Yu-Yao, Wu, Yi-Ling, Lin, Cheng-Wei, Chen, Pei-Chun, Chang, Chee Jen, Hsieh, Sheng-Hwu, Sun, Jui-Hung, Chen, Szu-Tah, Lin, Chia-Hung
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2018
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6192159/
https://ncbi.nlm.nih.gov/pubmed/30349614
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13098-018-0378-6
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados